ESC Professional Premium Access

HFpEF and HFmrEF: what’s new in treatment?

Event: ESC Congress 2022
Topic: Pathophysiology and Mechanisms
Session type: Abstract Sessions
Date: 27 August 2022
Time: 09:00 - 10:00

Congress Session

5 presentations in this session

Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial

Speaker: Mr A. van de Bovenkamp (Amsterdam, NL)
Thumbnail

Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial

Speaker: Associate Professor R. Wachter (Leipzig, DE)
Thumbnail

Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial

Speaker: Professor J. Butler (Jackson, US)
Thumbnail

Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction

Speaker: Doctor F. Lindberg (Stockholm, SE)
Thumbnail

The therapeutic potential of relaxin for heart failure with preserved ejection fraction

Speaker: Doctor G. Salama (Pittsburgh, US)
Thumbnail

5 speakers from this session

Mr Arno van de Bovenkamp

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))
0 follower

Associate Professor Rolf Wachter

University hospital Leipzig AoR, Leipzig (Germany)
8 presentations
0 follower

Professor Javed Butler

The University of Mississippi Medical Center, Jackson (United States of America)
71 presentations
5 followers

Doctor Felix Lindberg

Karolinska Institute, Stockholm (Sweden)
0 follower

Doctor Guy Salama

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)
0 follower

This platform is supported by

logo Novo Nordisk